<DOC>
	<DOC>NCT00970580</DOC>
	<brief_summary>The purpose of this study is to determine whether BIIB022, Paclitaxel and Carboplatin are effective in the treatment of Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer.</brief_summary>
	<brief_title>A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Antimitotic Agents</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Alkylating Agents</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Age &gt;/= 18 years old Treatmentnaive Stage IIIB/IV NonSmall Cell Lung Cancer ECOG Performance Status 0 or 1 History of another primary cancer within 3 years Any prior or concurrent investigational or standard therapy for treatment of NSCLC Prior antiIGF1R therapy Unstable diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>BIIB022</keyword>
	<keyword>Stage IV</keyword>
	<keyword>Taxol</keyword>
	<keyword>Stage IIIB</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>Treatment Naive</keyword>
	<keyword>Anti IGF1R</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Open Label</keyword>
	<keyword>IGF1R</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>Cytotoxic</keyword>
	<keyword>Mitotic Inhibitor</keyword>
	<keyword>Taxane</keyword>
	<keyword>Alkylating agent</keyword>
</DOC>